依那西普治疗强直性脊柱炎的疗效分析

目的 评价依那西普治疗强直性脊柱炎的效果和安全性.方法 86例强直性脊柱炎患者随机分为试验组和对照组(n=43).试验组予以非甾体类抗炎药(NSAIDs)和依那西普(25 mg,2次/周,上臂皮下注射)治疗;对照组予以NSAIDs和柳氮磺吡啶治疗.患者于治疗3个月后复查,分析腰痛发生率、腰部晨僵时间、Bath 强直性脊柱炎疾病活动指数(BASDAI)、Bath 强直性脊柱炎功能指数(BASFI)、红细胞沉降率(ESR)和C反应蛋白(CRP)的变化,观察有无不良反应.结果 与入组时比较,两组患者治疗3个月后腰痛发生率明显降低(P<0.05或P<0.01),腰部晨僵时间明显缩短(P<0.05),BASDAI和BASFI评分显著改善(P<0.05),ESR和CRP明显降低(P<0.05).治疗3个月后,试验组各项临床指标改善程度均明显优于对照组(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05).结论 依那西普治疗强直性脊柱炎的短期疗效显著,且不良反应轻微.

Efficacy of etanercept on ankylosing spondylitis

Objective To evaluate the efficacy and safety of etanercept in treatment of ankylosing spondylitis. Methods Eighty-six patients were randomized into experiment group and control group (n=43). Patients in experiment group were treated with non-steroidal antiinflammatory drugs (NSAIDs) and etanercept (25 mg, twice/week, subcutaneous injection in the upper arm), and those in control group were managed with NSAIDs and sulfasalazine. Reexaminations were performed after treatment for 3 months, and the prevalence of low back pain, time of morning stiffness, Bath ankylosing spondylitis disease activity index(BASDAI), Bath ankylosing spondylitis functional index(BASFI), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were analysed, and the prevalence of adverse effects was observed. Results Compared with those at administration, the prevalences of low back pain significantly reduced (P<0.05 or P<0.01), the time of morning stiffness significantly decreased (P<0.05), BASDAI and BASFI significantly improved, and ESR and CRP significantly decreased 3 months after treatment in both groups (P<0.05). After treatment for three months, the clinical parameters in experiment group were more favourable than those in control group (P<0.05). There was no significant difference in the prevalence of adverse effects between two groups (P>0.05). Conclusion Etanercept has favourable short-term therapeutic effects on ankylosing spondylitis with minor adverse effects.